Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

Blood

Volumn 119, Issue 14, 2012, Pages 3211-3218

  Damm, Frederik ^a,b   Kosmider, Olivier ^c,d,e,f   Gelsi Boyer, Véronique ^g,h   Renneville, Aline ⁱ   Carbuccia, Nadine ^g,h   Hidalgo Curtis, Claire ^j,k   Della Valle, Véronique ^a,b,l   Couronné, Lucile ^a,b,l   Scourzic, Laurianne ^a,b,l   Chesnais, Virginie ^d,e,f   Guerci Bresler, Agnes ^m   Slama, Bohrane ⁿ   Beyne Rauzy, Odile ^o   Schmidt Tanguy, Aline ^p   Stamatoullas Bastard, Aspasia ^q   Dreyfus, François ^r   Prébet, Thomas ^g,h   De Botton, Stéphane ^a   Vey, Norbert ^g,h   Morgan, Michael A ^s   Cross, Nicholas C P ^j,k   Preudhomme, Claude ⁱ   Birnbaum, Daniel ^g,h   Bernard, Olivier A ^a,b,l   Fontenay, Michaela ^c,d,e,f   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c Paris Descartes University   (France)

^d INSTITUT COCHIN   (France)

^e CNRS   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h AIX MARSEILLE UNIVERSITY   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^k WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^l UNIVERSITÉ PARIS SACLAY   (France)

^m UNIVERSITY HOSPITAL OF NANCY   (France)

ⁿ CENTRE HOSPITALIER D AVIGNON   (France)

^o CHU PURPAN   (France)

^p ANGERS UNIVERSITY HOSPITAL   (France)

^q Centre de Lutte Contre le Cancer Henri Becquerel   (France)

^r Centre de Lutte Contre le Cancer Henri Becquerel ^*  (France)

^s HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 3A; HEMOGLOBIN; MESSENGER RNA; MOLECULAR MARKER; PROTEIN; SF3B1 PROTEIN; SRSF2 PROTEIN; U2AF35 PROTEIN; UNCLASSIFIED DRUG; ZRSR2 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CHROMOSOME 20; CHROMOSOME DELETION; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RNA SPLICING; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION;

EID: 84859595800     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-400994     Document Type: Article

References (38)

1. Jadersten M, Hellstrom-Lindberg E. Myelodysplastic syndromes: biology and treatment. J Intern Med. 2009;265(3):307-328.
2. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
3. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009; 41(7):838-842.
4. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009; 145(6):788-800.
5. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42(8):665-667.
6. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010; 42(8):722-726.
7. Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153-1158.
8. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
9. Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010;95(10):1668-1674.
10. Thol F, Friesen I, Damm F, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011; 29(18):2499-2506.
11. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
12. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15): 1384-1395.
13. Wahl MC, Will CL, Luhrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009;136(4):701-718.
14. Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011;44(1):53-57.
15. Damm F, Thol F, Kosmider O, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications [published online ahead of print November 8, 2011]. Leukemia. doi:10.1038/leu.2011.321.
16. Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012; 119(2):569-572.
17. Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012;26(3):542-545.
18. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
19. Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114(15):3285-3291.
20. Sanada M, Suzuki T, Shih LY, et al. Gain-offunction of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460(7257): 904-908.
21. Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366(1):95-96.
22. Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24(5):1094-1096.
23. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-1148. (Pubitemid 40663494)
24. Damm F, Bunke T, Thol F, et al. Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia. Leukemia. 2012;26(2):289-295.
25. Quentin S, Cuccuini W, Ceccaldi R, et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood. 2011;117(15):e161-e170.
26. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986;5: 255-260.
27. COX D. Regression models and life tables. J R Stat Soc B . 1972;34:187-202.
28. Gelsi-Boyer V, Trouplin V, Roquain J, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010; 151(4):365-375.
29. Abdel-Wahab O, Kilpivaara O, Patel J, Busque L, Levine RL. The most commonly reported variant in ASXL1 (c. 1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia. 2010;24(9):1656-1657.
30. Pratcorona M, Abbas S, Sanders M, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica. 2012; 97(3):388-392.
31. Chou WC, Huang HH, Hou HA, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood. 2010;116(20):4086-4094.
32. Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/ myeloproliferative neoplasms. Blood. 2011; 118(24):6239-6246.
33. Thol F, Damm F, Ludeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011; 29(21):2889-2896.
34. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
35. Renneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association [published online ahead of print January 13, 2012]. Leukemia. doi:10.1038/ leu.2011.382.
36. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell selfrenewal and myeloid transformation. Cancer Cell. 2011;20(1):11-24.
37. Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25-38.
38. Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011;118(17):4509-4518.